- Home
- BRY vs ENGN Comparison
BRY vs ENGN Comparison
Compare BRY & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- ENGN
- Stock Information
- Founded
- BRY 1909
- ENGN 1999
- Country
- BRY United States
- ENGN Canada
- Employees
- BRY N/A
- ENGN N/A
- Industry
- BRY Oil & Gas Production
- ENGN
- Sector
- BRY Energy
- ENGN
- Exchange
- BRY Nasdaq
- ENGN Nasdaq
- Market Cap
- BRY 249.1M
- ENGN 321.5M
- IPO Year
- BRY N/A
- ENGN N/A
- Fundamental
- Price
- BRY $4.08
- ENGN $6.96
- Analyst Decision
- BRY Hold
- ENGN Buy
- Analyst Count
- BRY 2
- ENGN 8
- Target Price
- BRY $4.00
- ENGN $21.50
- AVG Volume (30 Days)
- BRY 2.2M
- ENGN 302.0K
- Earning Date
- BRY 11-06-2025
- ENGN 09-11-2025
- Dividend Yield
- BRY 2.93%
- ENGN N/A
- EPS Growth
- BRY N/A
- ENGN N/A
- EPS
- BRY 0.07
- ENGN N/A
- Revenue
- BRY $701,914,000.00
- ENGN N/A
- Revenue This Year
- BRY N/A
- ENGN N/A
- Revenue Next Year
- BRY N/A
- ENGN N/A
- P/E Ratio
- BRY $62.93
- ENGN N/A
- Revenue Growth
- BRY N/A
- ENGN N/A
- 52 Week Low
- BRY $2.11
- ENGN $2.65
- 52 Week High
- BRY $5.90
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- BRY 77.78
- ENGN 81.05
- Support Level
- BRY $3.15
- ENGN $5.52
- Resistance Level
- BRY $4.15
- ENGN $6.54
- Average True Range (ATR)
- BRY 0.16
- ENGN 0.55
- MACD
- BRY 0.10
- ENGN 0.14
- Stochastic Oscillator
- BRY 93.27
- ENGN 96.80
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.